GRAL · GRAIL, Inc.
$67.87
-0.37 (-0.54%)
At close · Aug 14
Market Cap
$3.03B
Shares
44.67M
GRAIL, Inc. Earnings Call Transcripts
Every quarterly earnings call for GRAIL, Inc. (GRAL) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▲42.6%
$31.97M
−$1.59B
'24 Q2
24-08-13
▲38.3%
$28.65M
−$125.69M
'24 Q3
24-11-12
·
$38.25M
−$97.07M
'24 Q4
25-02-20
▲19.1%
$31.84M
−$106.21M
'25 Q1
25-05-13
▲11.2%
$35.54M
−$113.98M
'25 Q2
25-08-12
▲26.3%
$36.19M
−$88.98M
'25 Q3
25-10-16
▲14%
$43.60M
−$99.18M
'25 Q4
26-01-12
▲28.1%
$40.78M
−$93.19M
'26 Q1
26-05-05
LATEST
▲25.7%
$44.69M
−$110.25M
'26 Q2
26-08-05
Conference
Investor event
2026-08-11
Canaccord Genuity 46th Annual Growth Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-08-05
GRAIL, Inc. Q2 FY2026 Earnings Call
Revenue
$44.69M
▲ 25.7% YoY Diluted EPS
$-2.56
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-09
Goldman Sachs 47th Annual Global Healthcare Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-05
GRAIL, Inc. Q1 FY2026 Earnings Call
Positive tone
FDA PMA review and approval timeline
NHS-Galleri and PATHFINDER 2 clinical data / ASCO
2026 guidance and conservatism
Revenue
$40.78M
▲ 28.1% YoY Diluted EPS
$-2.29
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-01-12
GRAIL, Inc. Q4 FY2025 Earnings Call
Positive tone
NHS-Galleri trial results
Commercial performance of Galleri
FDA PMA submission
Revenue
$43.60M*
▲ 14% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-10-16
GRAIL, Inc. Q3 FY2025 Earnings Call
Confident tone
Commercial volume and revenue growth
Clinical evidence - SIMPLIFY
Clinical evidence - PATHFINDER II
Revenue
$36.19M
▲ 26.3% YoY Diluted EPS
$-2.46
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-12
GRAIL, Inc. Q2 FY2025 Earnings Call
Confident tone
Galleri commercial volume growth
PATHFINDER 2 clinical study results
International expansion and tech transfer
Revenue
$35.54M
▲ 11.2% YoY Diluted EPS
$-3.18
Rev · 7q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-13
GRAIL, Inc. Q1 FY2025 Earnings Call
Positive tone
NHS-Galleri Trial Results
NHS Commercialization Partnership
Test Performance and Real World Evidence
Revenue
$31.84M
▲ 19.1% YoY Diluted EPS
$-3.10
Rev · 6q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-20
GRAIL, Inc. Q4 FY2024 Earnings Call
Positive tone
Galleri commercial momentum and test volume
Quest and TRICARE distribution/coverage expansion
Cash burn reduction and financial runway
Revenue
$38.25M*
Rev · 5q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-12
GRAIL, Inc. Q3 FY2024 Earnings Call
Positive tone
Galleri test demand and commercial performance
FDA approval pathway and registrational studies
Reimbursement strategy and legislation
Revenue
$28.65M
▲ 38.3% YoY Diluted EPS
$-3.94
Rev · 5q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-13
GRAIL, Inc. Q2 FY2024 Earnings Call
Positive tone
Galleri commercial performance and demand
FDA PMA submission and registrational studies
Corporate restructuring and cost reduction
Revenue
$31.97M
▲ 42.6% YoY Diluted EPS
$-51.06
Rev · 4q
Audio
Transcript
Slides
8-K10-Q
Showing 1–11 of 11 earnings calls
Key facts
CIK
1699031
CUSIP
384747101
13F (30d)
357 filings
345 filers
Visit website
Investor relations